Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Real-time Estimate Cboe BZX Other stock markets 20:10:48 13/09/2024 BST			5-day change	1st Jan Change
82.68 ^USD	+0.35%		+4.92%	+1.95%

01:00pm	Marengo Therapeutics, Inc. Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Invikafusp alfa and Trodelvy in Both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers	CI
09-12	Gilead Sciences Says Twice-Yearly HIV Treatment Lenacapavir Reduces Infections by 96%	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Marengo Therapeutics, Inc. Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Invikafusp alfa and Trodelvy in Both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers	12:00pm	CI
Ex-dividend day	12/09/2024	FA
Gilead Sciences Says Twice-Yearly HIV Treatment Lenacapavir Reduces Infections by 96%	09-12	MT
Raymond James Raises Gilead Sciences' Price Target to $94 From $93, Outperform Rating Maintained	09-11	MT
Gilead Sciences Seeks Bolt-On Acquisitions	09-10	CI
Gilead Sciences, Genesis Therapeutics Sign Deal to Discover, Develop Novel Therapies	09-10	MT
Gilead, Genesis Therapeutics to Use AI to Discover Novel Therapies	09-10	DJ
RBC Raises Price Target on Gilead Sciences to $74 From $72, Keeps Sector Perform Rating	09-04	MT
Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer	09-03	CI
Health Care Up Amid Shift From Tech to Biotech -- Health Care Roundup	08-29	DJ
Jefferies Adjusts Price Target on Gilead Sciences to $95 From $90, Maintains Buy Rating	08-28	MT
Gilead Sciences Collaborates With PANTHERx Rare for Livdelzi Distribution	08-16	MT
Pantherx Rare Partnering with Gilead Sciences, Inc. for the Distribution of Livdelzi	08-16	CI
Incyte's blood cancer drug succeeds late-stage trial	08-16	RE
Gilead Sciences Receives Accelerated Approval from FDA	08-14	DJ
Gilead?S Livdelzi Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA	08-14	CI
Gilead gets US FDA approval for inflammatory liver disease drug	08-14	RE
US FDA approves Gilead's liver disease drug	08-14	RE
Global markets live: Apple, Walt Disney, BHP, Intel, Take-Two...	08-09
Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.	08-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Highlights

Filters